- Home
- EQ vs MOVE Comparison
EQ vs MOVE Comparison
Compare EQ & MOVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- MOVE
- Stock Information
- Founded
- EQ 2017
- MOVE 2018
- Country
- EQ United States
- MOVE United States
- Employees
- EQ N/A
- MOVE N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- MOVE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- EQ Health Care
- MOVE Health Care
- Exchange
- EQ Nasdaq
- MOVE Nasdaq
- Market Cap
- EQ 24.8M
- MOVE 25.9M
- IPO Year
- EQ 2018
- MOVE 2021
- Fundamental
- Price
- EQ $0.59
- MOVE $5.66
- Analyst Decision
- EQ Buy
- MOVE Buy
- Analyst Count
- EQ 2
- MOVE 1
- Target Price
- EQ $5.00
- MOVE $30.00
- AVG Volume (30 Days)
- EQ 117.7K
- MOVE 89.9K
- Earning Date
- EQ 11-13-2024
- MOVE 11-14-2024
- Dividend Yield
- EQ N/A
- MOVE N/A
- EPS Growth
- EQ N/A
- MOVE N/A
- EPS
- EQ N/A
- MOVE N/A
- Revenue
- EQ $45,914,000.00
- MOVE $902,000.00
- Revenue This Year
- EQ $4.76
- MOVE N/A
- Revenue Next Year
- EQ N/A
- MOVE $545.31
- P/E Ratio
- EQ N/A
- MOVE N/A
- Revenue Growth
- EQ 7.70
- MOVE N/A
- 52 Week Low
- EQ $0.56
- MOVE $2.80
- 52 Week High
- EQ $3.25
- MOVE $12.75
- Technical
- Relative Strength Index (RSI)
- EQ 33.48
- MOVE 54.55
- Support Level
- EQ $0.56
- MOVE $4.80
- Resistance Level
- EQ $0.67
- MOVE $6.24
- Average True Range (ATR)
- EQ 0.05
- MOVE 0.47
- MACD
- EQ -0.00
- MOVE -0.07
- Stochastic Oscillator
- EQ 15.79
- MOVE 39.35
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About MOVE Movano Inc.
Movano Inc is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. its initial commercial product in development is the Evie Ring, a wearable designed specifically for women. The Evie Ring combines health and wellness metrics to give a full picture of one's health, which includes resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.